Bristol entecavir review
Executive Summary
FDA's Antiviral Drugs Advisory Committee will consider Bristol-Myers Squibb's entecavir for the treatment of chronic hepatitis B infection on March 11. Bristol announced its submission of entecavir Oct. 4, 2004; the application is receiving a six-month priority review. The meeting will be held at the Hilton in Gaithersburg, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...